AAAAAA

   
Results: 1-16 |
Results: 16
PPAR gamma/RXR as a molecular target for diabetes
Authors: Lenhard, JM
Citation: Jm. Lenhard, PPAR gamma/RXR as a molecular target for diabetes, RECEPT CHAN, 7(4), 2001, pp. 249-258
Metabolic complications associated with antiretroviral therapy
Authors: Jain, RG Furfine, ES Pedneault, L White, AJ Lenhard, JM
Citation: Rg. Jain et al., Metabolic complications associated with antiretroviral therapy, ANTIVIR RES, 51(3), 2001, pp. 151-177
Chapter 13. In vitro and in vivo approaches to studying antiretroviral therapy (ART)-induced metabolic complications
Authors: Weiel, JE Lenhard, JM
Citation: Je. Weiel et Jm. Lenhard, Chapter 13. In vitro and in vivo approaches to studying antiretroviral therapy (ART)-induced metabolic complications, ANNU REP M, 36, 2001, pp. 129-137
Abacavir and diabetes.
Authors: Hetherington, SV Lenhard, JM Powell, GS
Citation: Sv. Hetherington et al., Abacavir and diabetes., N ENG J MED, 344(2), 2001, pp. 143-144
HIV protease inhibitors stimulate hepatic triglyceride synthesis
Authors: Lenhard, JM Croom, DK Weiel, JE Winegar, DA
Citation: Jm. Lenhard et al., HIV protease inhibitors stimulate hepatic triglyceride synthesis, ART THROM V, 20(12), 2000, pp. 2625-2629
Bone mineral loss in HIV-positive patients receiving antiretroviral therapy
Authors: Weiel, JE Lenhard, JM
Citation: Je. Weiel et Jm. Lenhard, Bone mineral loss in HIV-positive patients receiving antiretroviral therapy, AIDS, 14(14), 2000, pp. 2218-2219
HIV protease inhibitors block adipogenesis and increase lipolysis in vitro
Authors: Lenhard, JM Furfine, ES Jain, RG Ittoop, O Orband-Miller, LA Blanchard, SG Paulik, MA Weiel, JE
Citation: Jm. Lenhard et al., HIV protease inhibitors block adipogenesis and increase lipolysis in vitro, ANTIVIR RES, 47(2), 2000, pp. 121-129
Dietary fat alters HIV protease inhibitor-induced metabolic changes in mice
Authors: Lenhard, JM Croom, DK Weiel, JE Spaltenstein, A Reynolds, DJ Furfine, ES
Citation: Jm. Lenhard et al., Dietary fat alters HIV protease inhibitor-induced metabolic changes in mice, J NUTR, 130(9), 2000, pp. 2361-2366
Stimulation of vitamin A(1) acid signaling by the HIV protease inhibitor indinavir
Authors: Lenhard, JM Weiel, JE Paulik, MA Furfine, ES
Citation: Jm. Lenhard et al., Stimulation of vitamin A(1) acid signaling by the HIV protease inhibitor indinavir, BIOCH PHARM, 59(9), 2000, pp. 1063-1068
Therapeutic approaches to Type 2 diabetes mellitus
Authors: Rose, ML Paulik, MA Lenhard, JM
Citation: Ml. Rose et al., Therapeutic approaches to Type 2 diabetes mellitus, EXPERT OP T, 9(9), 1999, pp. 1223-1236
A peroxisome proliferator-activated receptor gamma ligand inhibits adipocyte differentiation
Authors: Oberfield, JL Collins, JL Holmes, CP Goreham, DM Cooper, JP Cobb, JE Lenhard, JM Hull-Ryde, EA Mohr, CP Blanchard, SG Parks, DJ Moore, LB Lehmann, JM Plunket, K Miller, AB Milburn, MV Kliewer, SA Willson, TM
Citation: Jl. Oberfield et al., A peroxisome proliferator-activated receptor gamma ligand inhibits adipocyte differentiation, P NAS US, 96(11), 1999, pp. 6102-6106
The RXR agonist LG100268 causes hepatomegaly, improves glycaemic control and decreases cardiovascular risk and cachexia in diabetic mice suffering from pancreatic beta-cell dysfunction
Authors: Lenhard, JM Lancaster, ME Paulik, MA Weiel, JE Binz, JG Sundseth, SS Gaskill, BA Lightfoot, RM Brown, HR
Citation: Jm. Lenhard et al., The RXR agonist LG100268 causes hepatomegaly, improves glycaemic control and decreases cardiovascular risk and cachexia in diabetic mice suffering from pancreatic beta-cell dysfunction, DIABETOLOG, 42(5), 1999, pp. 545-554
A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-gamma reverses the diabetic phenotype of the Zucker diabetic fatty rat
Authors: Brown, KK Henke, BR Blanchard, SG Cobb, JE Mook, R Kaldor, I Kliewer, SA Lehmann, JM Lenhard, JM Harrington, WW Novak, PJ Faison, W Binz, JG Hashim, MA Oliver, WO Brown, HR Parks, DJ Plunket, KD Tong, WQ Menius, JA Adkison, K Noble, SA Willson, TM
Citation: Kk. Brown et al., A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-gamma reverses the diabetic phenotype of the Zucker diabetic fatty rat, DIABETES, 48(7), 1999, pp. 1415-1424
N-(2-benzoylphenyl)-L-tyrosine PPAR gamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents
Authors: Henke, BR Blanchard, SG Brackeen, MF Brown, KK Cobb, JE Collins, JL Harrington, WW Hashim, MA Hull-Ryde, EA Kaldor, I Kliewer, SA Lake, DH Leesnitzer, LM Lehmann, JM Lenhard, JM Orband-Miller, LA Miller, JF Mook, RA Noble, SA Oliver, W Parks, DJ Plunket, KD Szewczyk, JR Willson, TM
Citation: Br. Henke et al., N-(2-benzoylphenyl)-L-tyrosine PPAR gamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents, J MED CHEM, 41(25), 1998, pp. 5020-5036
N-(2-benzoylphenyl)-L-tyrosine PPAR gamma agonists. 2. Structure-activity relationship and optimization of the phenyl alkyl ether moiety
Authors: Collins, JL Blanchard, SG Boswell, GE Charifson, PS Cobb, JE Henke, BR Hull-Ryde, EA Kazmierski, WM Lake, DH Leesnitzer, LM Lehmann, J Lenhard, JM Orband-Miller, LA Gray-Nunez, Y Parks, DJ Plunkett, KD Tong, WQ
Citation: Jl. Collins et al., N-(2-benzoylphenyl)-L-tyrosine PPAR gamma agonists. 2. Structure-activity relationship and optimization of the phenyl alkyl ether moiety, J MED CHEM, 41(25), 1998, pp. 5037-5054
N-(2-benzoylphenyl)-L-tyrosine PPAR gamma agonists. 3. Structure-activity relationship and optimization of the N-aryl substituent
Authors: Cobb, JE Blanchard, SG Boswell, EG Brown, KK Charifson, PS Cooper, JP Collins, JL Dezube, M Henke, BR Hull-Ryde, EA Lake, DH Lenhard, JM Oliver, W Oplinger, J Pentti, M Parks, DJ Plunket, KD Tong, WQ
Citation: Je. Cobb et al., N-(2-benzoylphenyl)-L-tyrosine PPAR gamma agonists. 3. Structure-activity relationship and optimization of the N-aryl substituent, J MED CHEM, 41(25), 1998, pp. 5055-5069
Risultati: 1-16 |